Brief: Nicox Updates On Fera's Evaluation Of Naproxcinod

Nicox SA

30/04/2021 06:39

April 30 (Reuters) - NICOX SA  NCOX.PA :
    * NICOX UPDATES ON FERA PHARMACEUTICALS' CONTINUING
EVALUATION OF
NAPROXCINOD
    * NICOX IS ELIGIBLE TO POTENTIALLY RECEIVE A SINGLE $40 MLN
SALES-BASED MILESTONE IF NAPROXCINOD REACHES $1 BLN YEARLY SALES
(FOR ANY INDICATION) IN U.S.
    * NICOX IS ELIGIBLE TO POTENTIALLY RECEIVE ROYALTIES OF 7%
ON NET
SALES OF NAPROXCINOD IN U.S.

Source text for Eikon:  ID:nGNX4z6yzq 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))